Therapeutic Targeting of Lipid Nanoparticles
US-2024131181-A1 · Apr 25, 2024 · US
Stable activatable particles as radiotherapeutic agents for the treatment of disease
US9327038B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9327038-B2 |
| Application number | US-201213660198-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2012 |
| Priority date | Oct 25, 2011 |
| Publication date | May 3, 2016 |
| Grant date | May 3, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation.
First claim
Opening claim text (preview).
That which is claimed: 1. A stable activatable particle comprising an activatable radionuclide precursor and a carrier moiety, wherein said activatable radionuclide precursor comprises a radionuclide selected from the group consisting of 23 Na, 31 P, 56 Fe, 74 Se, 85 Rb, 88 Sr, 89 Y, 127 I, 139 La, 141 Pr, 149 Sm, 150 Sm, 152 Sm, 164 Dy, 165 Ho, 168 Er, 175 Lu, 185 Re, 187 Re, 197 Au, 203 Tl, and any combination thereof, conjugated to a hydrophobic and/or lipophilic moiety selected from the group consisting of acetylacetone, ethyl acetoacetate, 3-methyl-2,4-pentanedione, 3-ethyl-2,4-pentanedione, 2,4-hexanedione, and diethyl malonate, and wherein said carrier moiety is a silica particle having a diameter of about 1 nm to about 500 nm. 2. The stable activatable particle of claim 1 , wherein said activatable radionuclide precursor comprises a radionuclide selected from the group consisting of 31 P, 88 Sr, 89 Y, 127 I, 149 Sm, 150 Sm, 152 Sm, 164 Dy, 165 Ho, 175 Lu, and any combination thereof. 3. The stable activatable particle of claim 1 , wherein said activatable radionuclide precursor comprises 165 Ho. 4. The stable activatable particle of claim 1 , wherein said activatable radionuclide precursor is holmium-165 acetylacetonate ( 165 Ho(AcAc) 3 ). 5. The stable activatable particle of claim 1 , wherein said carrier moiety is a mesoporous silica particle. 6. The stable activatable particle of claim 1 , wherein said carrier moiety comprises a targeting agent. 7. The stable activatable particle of claim 6 , wherein said targeting agent is a tumor-targeting agent. 8. A radiotherapeutic agent produced by activating the stable activatable particle of claim 1 . 9. The radiotherapeutic agent of claim 8 , wherein activating the stable activatable particle comprises neutron activation. 10. A pharmaceutical composition comprising the stable activatable particle of claim 1 . 11. A pharmaceutical composition comprising the radiotherapeutic agent of claim 8 .
Assignees
Inventors
Classifications
- A61K51/1244Primary
microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title
Micelles, e.g. phospholipidic or polymeric micelles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9327038B2 cover?
- The present invention provides radiotherapeutic agents and compositions and methods for making and using the same. In some embodiments, the radiotherapeutic agent is a nanoparticle comprising a radionuclide and a carrier moiety. In some embodiments, the radionuclide is produced by activating a stable activatable particle via neutron activation.
- Who is the assignee on this patent?
- Univ North Carolina
- What technology area does this patent fall under?
- Primary CPC classification A61K51/1244. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 03 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).